Modern concepts about chronic prostate inflammation

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

The review presents modern aspects of the epidemiology, pathogenesis, diagnosis, drug treatment of chronic prostatitis. We performed a comprehensive search using multiple databases. There is still no single pharmacological approach in the management of patients with chronic prostate. Future clinical trials should include a full report of their methods including adequate masking, consistent assessment of all patient-important outcomes including potential treatment-related adverse events and appropriate sample sizes.

About the authors

Yuri Yu. Vinnik

Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; Krasnoyarsk Regional Dermatovenerological Dispensary No. 1

Email: vinnik33@mail.ru
ORCID iD: 0000-0002-8135-0445
SPIN-code: 7946-6230

Dr. Sci. (Med.), Professor, Prof. V.I. Prokhorenkov Department of Dermatovenereology with a course in cosmetology and postgraduate education; Chief Physician

Russian Federation, Krasnoyarsk; Krasnoyarsk

Andrey V. Kuzmenko

N.N. Burdenko Voronezh State Medical University

Email: kuzmenkoav09@yandex.ru
ORCID iD: 0000-0002-7927-7015
SPIN-code: 6981-7490
Scopus Author ID: 7003998310

Dr. Sci. (Med), Professor of the Department of Urology

Russian Federation, Voronezh

Andrei A. Amelchenko

Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University

Author for correspondence.
Email: aroun88@yandex.ru
ORCID iD: 0000-0003-2867-4317
SPIN-code: 6601-4370

Postgraduate Student, Department of Urology, Andrology and Sexology

Russian Federation, Krasnoyarsk

References

  1. Doiron RC, Shoskes DA, Nickel JC. Male CP/CPPS: where do we stand? World J Urol. 2019;37(6):1015–1022. doi: 10.1007/s00345-019-02718-6
  2. Krieger JN, Lee SWH, Jeon J, et al. Epidemiology of prostatitis. Int J Antimicrob Agents. 2008;31(S1): S85–90. doi: 10.1016/j.ijantimicag.2007.08.028
  3. Nickel JC, Wagenlehner F, Pontari M, et al. Male chronic pelvic pain syndrome (CPPS). In: Male lower urinary tract symptoms (LUTS). An international Consultation on Male LUTS. Chapple C, Abrams P, editors. Fukuoka, Japan; Sept 30–Oct 4, 2012. Montreal: Société Internationale d’Urologie (SIU), 2013b. P. 331–372.
  4. McNaughton Collins M, Pontari MA, O’Leary MP, et al. Quality of life is impaired in men with chronic prostatitis: the Chronic Prostatitis Collaborative Research Network. J Gen Intern Med. 2001;16:656–662. doi: 10.1111/j.1525-1497.2001.01223.x
  5. Kul’chavenya EV, Holtobin DP, Shevchenko SYu, et al. The frequency of the chronic prostatitis in the outpatient practice. Experimental and clinical urology. 2015;(1):16–18. (In Russ.)
  6. Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA. 1999;282(3):236–237. doi: 10.1001/jama.282.3.236
  7. Meares EM, Stamey TA. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol. 1968;5(5):492–518.
  8. Drach GW, Fair WR, Meares EM, et al. Classification of benign disease associated with prostatic pain: prostatitis or prostatodynia? J Urol. 1978;120(2):266. doi: 10.1016/S0022-5347(17)57135-9
  9. Clemens JQ, Meenan RT, O’Keeffe Rosetti MC, et al. Incidence and clinical characteristics of National Institutes of Health type III prostatitis in the community. J Urol. 2005;174(6):2319–2322. doi: 10.1097/01.ju.0000182152.28519.e7
  10. Kadyrov ZA, Stepanov VS, Ramishvili SV, Mashaneishvili SG. Diagnostics of chronic nonbacterial prostatitis. Andrology and Genital Surgery. 2019;20(3):36–42. (In Russ.) doi: 10.17650/2070-9781-2019-20-3-36-42
  11. Polackwich AS, Shoskes DA. Chronic prostatitis/chronic pelvic pain syndrome: a review of evaluation and therapy. Prostate Cancer Prostatatic Dis. 2016;19(2):132–138. doi: 10.1038/pcan.2016.8.
  12. Multi-modal therapy options for CP/CPPS patients, classified by UPOINT phenotype. Adapted with permission from Can Urol Assoc J. 2018;12(6–3):161–163. doi: 10.5489/cuaj.5325.
  13. Davis SNP, Binik YM, Amsel R, Carrier S. Is a sexual dysfunction domain important for quality of life in men with urological chronic pelvic pain syndrome? Signs “UPOINT” to yes. J Urol. 2013;189(1):146–151. doi: 10.1016/j.juro.2012.08.083
  14. Samplaski MK, Li J, Shoskes DA. Inclusion of erectile domain to UPOINT phenotype does not improve correlation with symptom severity in men with chronic prostatitis/chronic pelvic pain syndrome. Urology. 2011;78(3):653–658. doi: 10.1016/j.urology.2011.04.016
  15. Zhang Z, Su X, Cai C, Wang Z. Application analysis of UPOINT system in Chinese type III prostatitis patients: a single center experience. Comput Math Methods Med. 2022;2022:9227032. doi: 10.1155/2022/9227032
  16. Magri V, Marras E, Restelli A, et al. Multimodal therapy for category III chronic prostatitis/chronic pelvic pain syndrome in UPOINTS phenotyped patients. Exp Ther Med. 2015;9(3):658–666. doi: 10.3892/etm.2014.2152
  17. Franco JVA, Turk T, Jung JH, et al. Non-pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a Cochrane systematic review. BJU Int. 2019;124(2):197–208. doi: 10.1111/bju.14492
  18. Nickel JС. The Prostatitis Manual: A Practical Guide to Management of Prostatitis/Chronic Pelvic Pain Syndrome. Oxford: Bladon Medical Publishing, 2002. 117 p.
  19. Santillo VM, Lowe FC. The management of chronic prostatitis in men with HIV. Curr Urol Rep. 2006;7(4):313–319. doi: 10.1007/s11934-996-0011-3
  20. Kadyrov ZA, Kryachko AA, Aliev ZO, et al. Clinical laboratory and instrumental studies in patients with chronic prostatitis and hemorrhoids. Andrology and Genital Surgery. 2016;17(2):34–38. (In Russ.) doi: 10.17650/2070-9781-2016-17-2-34-38
  21. Porter CM, Shrestha E, Peiffer LB, Sfanos KS. The microbiome in prostate inflammation and prostate cancer. Prostate Cancer Prostatic Dis. 2018;21(3):345–354. doi: 10.1038/s41391-018-0041-1
  22. Agarwal A, Rana M, Qiu E, et al. Role of oxidative stress, infection and inflammation in male infertility. Andrologia. 2018;50(11): e13126. doi: 10.1111/and.13126
  23. Chen Y, Li J, Hu Y, et al. Multi-factors including inflammatory/immune, hormones, tumor-related proteins and nutrition associated with chronic prostatitis NIH IIIa+b and IV based on FAMHES project. Sci Rep. 2017;7(1):9143. doi: 10.1038/s41598-017-09751-8
  24. Bukharin OV, Kuzmin MD, Perunova NB, et al. Diagnostic cytokine marker of male infertility — interleukin 4. Klin Lab Diagn. 2022;67(3):151–157. doi: 10.51620/0869-2084-2022-67-3-151-157
  25. Yip K, Cohen RE, Pillinger MH. Asymptomatic hyperuricemia: is it really asymptomatic? Curr Opin Rheumatol. 2020;32(1): 71–79. doi: 10.1097/BOR.0000000000000679
  26. Tyagi P, Motley SS, Koyama T, et al. Molecular correlates in urine for the obesity and prostatic inflammation of BPH/LUTS patients. Prostate. 2018;78(1):17–24. doi: 10.1002/pros.23439
  27. Gallo L. Effectiveness of diet, sexual habits and lifestyle modifications on treatment of chronic pelvic pain syndrome. Prostate Cancer Prostatic Dis. 2014;17(3):238–245. doi: 10.1038/pcan.2014.18
  28. Konoplya AI, Shatokhin MN, Gavriliuk VP, Кaraulov AV. Immunologic problems of the chronic prostatitis. Immunopathology, allergology, infectology. 2015;(2):29–34. (In Russ.)
  29. Tsukanov AYu, Lyashev RV. Disorders of venous blood flow as a cause of chronic abacterial prostatitis (chronic pelvic pain syndrome). Urologiia. 2014;(4):33–38. (In Russ.)
  30. Vinnik YY, Prokhorenkov VI. Evaluation of pathogenetic factors of chronic prostatitis development. Russian Journal of Skin and Venereal Diseases. 2013;16(1):61–65. (In Russ.) doi: 10.17816/dv36820
  31. Alshahrani S, McGill J, Agarwal A. Prostatitis and male infertility. J Reprod Immunol. 2013;100(1):30–36. doi: 10.1016/j.jri.2013.05.004
  32. Verze P, Cai T, Lorenzetti S. The role of the prostate in male fertility, health and disease. Nat Rev Urol. 2016;13(7):379–386. doi: 10.1038/nrurol.2016.89
  33. Motrich RD, Salazar FC, Breser ML, et al. Implications of prostate inflammation on male fertility. Andrologia. 2018;50(11): e13093. DOI: 10.1111/ and.13093
  34. Tvrdá E, Lovíšek D, Gálová E, et al. Possible implications of bacteriospermia on the sperm quality, oxidative characteristics, and seminal cytokine network in normozoospermic men. Int J Mol Sci. 2022;23(15):8678. doi: 10.3390/ijms23158678
  35. Condorelli RA, Russo GI, Calogero AE, et al. Chronic prostatitis and its detrimental impact on sperm parameters: A systematic review and meta-analysis. J Endocrinol Invest. 2017;40(11):1209–1218. doi: 10.1007/s40618-017-0684-0
  36. Shang Y, Liu C, Cui D, et al. The effect of chronic bacterial prostatitis on semen quality in adult men: a meta-analysis of case-control studies. Sci Rep. 2014;4:7233. doi: 10.1038/srep07233
  37. Alyaev YuG, Glybochko PV, Pushkar’ DYu. Urologiya. RossiĬskie klinicheskie rekomendatsii. Moscow: GEHOTAR-Media, 2015. 480 p. (In Russ.)
  38. Kuznetskii YuYa. Klinicheskaya kartina. In: Prostatit. P. A. Shchapleva, editor. Moscow: MEDpress-inform, 2007. P. 108–113. (In Russ.)
  39. Belousov II, Shangichev AV, Kogan MI. Clinical characteristics of inflammatory and noninflammatory forms of chronic abacterial prostatitis. Bashkortostan Medical Journal. 2013;8(2):14–17. (In Russ.)
  40. Thin RN. The chronic prostatitis syndroms. J R Army Med Corps. 1997;143(3):155–159. doi: 10.1136/jramc-143-03-06
  41. Trapeznikova MF, Dutov VV, Dolgov AG, Urenkov SB. Prostamole-uno treatment in patients with prostatic adenoma and chronic non-infectious prostatitis. Urologiia. 2008;(5):39–42. (In Russ.)
  42. Lasareva VA, Gridneva TD, Udut VV. Possibility to prescribe pantohaematogen for correction of copulative and reproductive functions in patients with chronic prostatitis. Kazan medical journal. 2007;88(3):263–266. (In Russ.)
  43. Belousov II, Chernogubova EA, Kogan MI. The role of endothelial dysfunction in the pathogenesis of non-inflammatory form of chronic abacterial prostatitis. Urologiia. 2013;(3):39–42. (In Russ.)
  44. Matsukawa Y, Naito Y, Funahashi Y, et al. Comparison of cernitin pollen extract vs tadalafil therapy for refractory chronic prostatitis/chronic pelvic pain syndrome: A randomized, prospective study. Neurourol Urodyn. 2020;39(7):1994–2002. doi: 10.1002/nau.24454
  45. Riegel B, Bruenahl CA, Ahyai S, et al. Assessing psychological factors, social aspects and psychiatric co-morbidity associated with Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) in men — a systematic review. J Psychosom Res. 2014;77(5):333–350. doi: 10.1016/j.jpsychores.2014.09.012
  46. Dun R-L, Tsai J, Hu X-H, et al. A systematic review of cross-cultural adaptation of the National Institutes of Health Chronic Prostatitis Symptom Index. Health Qual Life Outcomes. 2021;19(1):159. doi: 10.1186/s12955-021-01796-8
  47. Loran OB, Segal AS. Sistema summarnoi otsenki simptomov pri khronicheskom prostatite (SOS — KHP). Urologiia. 2001;(5):16–19. (In Russ.)
  48. Raheem OA, Natale C, Dick B, et al. Novel treatments of erectile dysfunction: review of the current literature. Sex Med Rev. 2021;9(1):123–132. doi: 10.1016/j.sxmr.2020.03.005
  49. Vasil’chenko GS, Botneva IL, Vinnik YuYu, et al. Obshchaya seksopatologiya: rukovodstvo dlya vrachei. Moscow: Meditsina, 2005. 512 p. (In Russ.)
  50. Rees J, Abrahams M, Doble A, et al. Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJU Int. 2015;116(4):509–525. doi: 10.1111/bju.13101
  51. McNaughton Collins M, Fowler FJ, Elliott DB, et al. Diagnosing and treating chronic prostatitis: do Urologists use the fourglass test? Urology. 2000;55(3):403–407. doi: 10.1016/S0090-4295(99)00536-1
  52. Nickel JC, Shoskes D, Wang Y, et al. How does the premassage and post-massage 2-glass test compare to the Meares–Stamey 4-glass test in men with chronic prostatitis/chronic pelvic pain syndrome? J Urol. 2006;176(1):119–124. doi: 10.1016/S0022-5347(06)00498-8
  53. Evdokimov VV. Demografiya i khronicheskii prostatit. Difficult Patient. 2010;(11):57–64. (In Russ.)
  54. Grabe M, Bartoletti R, Bjerklund Johansen TE, et al. Guidelines on urological infections. European Association of Urology, 2015. P. 42–46.
  55. Vinnik YuYu, Prohorenkov VI, Nikolaev VG. Clinical-laboratory features of chronic urethrogenic prostatitis on the background of complex treatment with ozonetherapy. Siberian Medical Review. 2015;(5):80–84. (In Russ.) doi: 10.20333/25000136-2015-5-80-84
  56. Anothaisintawee T, Attia J, Nickel JC, et al. Management of chronic prostatitis / chronic pelvic pain syndrome: a systematic review and network meta-analysis. JAMA. 2011;305(1):78–86. doi: 10.1001/jama.2010.1913.
  57. Bozhedomov VA. Modern opportunities for the treatment of chronic prostatitis. Andrology and Genital Surgery. 2016;17(3):10–22. (In Russ.) doi: 10.17650/2070-9781-2016-17-3-10-22
  58. Pochernikov DG, Getman VV, Postovoytenko NT, et al. Comparative analysis of the rate of microorganism detection in the prostatic fluid and ejaculate using real-time polymerase chain reaction in patients with category IV chronic prostatitis. Andrology and Genital Surgery. 2020;21(1):42–48. (In Russ.) doi: 10.17650/2070-9781-2020-21-1-42-48
  59. Osipov GA, Rodionov GG. Microenvironment in human health and disease by mass spectrometry of microbial markers. Mediko-biologicheskie i sotsial’no-psikhologicheskie problemy bezopasnosti v chrezvychainykh situatsiyakh. 2013;(2):43–53. (In Russ.)
  60. Rizoev HH, Nazarov TN. Vozmozhnosti transrektal’nogo ul’trazvukovogo issledovaniya v diagnostike i lechenii khronicheskogo obstruktivnogo prostatita. Andrology and Genital Surgery. 2010;11(2):99. (In Russ.)
  61. Lebovici A, Csutak C, Popa P, et al. Magnetic resonance imaging characteristics of chronic prostatitis in patients under the age of 50: is it more than the eye can see? Acta Radiol. 2022;63(6): 839–846. doi: 10.1177/02841851211010397
  62. Clemente A, Renzulli M, Reginelli A, et al. Chronic prostatitis/pelvic pain syndrome: MRI findings and clinical correlations. Andrologia. 2019;51(9): e13361. doi: 10.1111/and.13361
  63. Uysal A, Karaosmanoğlu AD, Karcaaltıncaba M, et al. Prostatitis, the great mimicker of prostate cancer: can we differentiate them quantitatively with multiparametric MRI? AJR Am J Roentgenol. 2020;215(5):1104–1112. doi: 10.2214/AJR.20.22843
  64. Perletti G, Marras E, Wagenlehner FME, Magri V. Antimicrobial therapy for chronic bacterial prostatitis. Cochrane Database Syst Rev. 2013;12(8): CD009071. doi: 10.1002/14651858.CD009071.pub2
  65. Gardiner BJ, Mahony AA, Ellis AG, et al. Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis? Clin Infect Dis. 2014;58(4): e101–105. doi: 10.1093/cid/cit704
  66. Kwan ACF, Beahm NP. Fosfomycin for bacterial prostatitis: a review. Int J Antimicrob Agents. 2020;56(4):106106. doi: 10.1016/j.ijantimicag.2020.106106
  67. Alyaev YuG, Vinarov AZ, Sinitsyn VE, et al. Multispiralnaya miktsionnaya komp’yuternaya tsistouretrografiya v diagnostike intraprostaticheskogo reflyuksa. Andrology and Genital Surgery. 2004;5(4):50–51. (In Russ.)
  68. Ismail M, Mackenzie K, Hashim H. Contemporary treatment options for chronic prostatitis/chronic pelvic pain syndrome. Drugs Today (Barc). 2013;49(7):457–462. doi: 10.1358/dot.2013.49.7.1990152
  69. Alexander RB, Propert KJ, Schaeffer AJ, et al.; Chronic Prostatitis Collaborative Research Network. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial. Ann Intern Med. 2004;141(8):581–589. doi: 10.7326/0003-4819-141-8-200410190-00005
  70. Nickel JC, Krieger JN, McNaughton-Collins M, et al.; Chronic Prostatitis Collaborative Research Network. Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome. N Engl J Med. 2008;359(25):2663–2673. doi: 10.1056/NEJMoa0803240
  71. Kogan MI, Belousov II. Comparative, single-centre, randomized, placebo-controlled study of efficacy and safety of flupirtine and celecoxib in CPPS/CP IIIB. Eur Urol Suppl. 2012;11(1):e45–e45a. doi: 10.1016/S1569-9056(12)60044-X
  72. Tkachuk VN, Tkachuk IN, Borovets SY. The results of 12-year study of the efficacy of Vitaprostin patients with chronic prostatitis. Urology reports (St. Petersburg). 2016;6(4):5–9. (In Russ.) doi: 10.17816/uroved645-9
  73. Lopatkin NA, Apolikhin ОI, Sivkov AV, et al. Results of a multicenter trial of serenoa repens extract (permixon) in patients with chronic abacterial prostatitis. Urologiia. 2007;(5):1–7. (In Russ.)
  74. Chubirko AG, Reznikov KM, Shiryaev OY. Dynamics of anxiety coefficients of patients with chronic prostatitis which is depend on realising therapy. Journal of New Medical Technologies. 2012;19(2):271–272. (In Russ.)
  75. Kurita M, Yamaguchi H, Okamoto K, et al. Chronic pelvic pain and prostate inflammation in rat experimental autoimmune prostatitis: Effect of a single treatment with phosphodiesterase 5 inhibitors on chronic pelvic pain. Prostate. 2018;78(15):1157–1165. doi: 10.1002/pros.23690
  76. Franco JVA, Turk T, Jung JH, et al. Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome. Cochrane Database Syst Rev. 2019;10(10):CD012552. doi: 10.1002/14651858.CD012552.pub2
  77. Letkiewicz S, Międzybrodzki R, Kłak M, et al. The perspectives of the application of phage therapy in chronic bacterial prostatitis. FEMS Immunol Med Microbiol. 2010;60(2):99–112. doi: 10.1111/j.1574-695X.2010.00723.x
  78. Górski A, Jończyk-Matysiak E, Łusiak-Szelachowska M, et al. Phage Therapy in Prostatitis: Recent Prospects. Front Microbiol. 2018;9:1434. doi: 10.3389/fmicb.2018.01434
  79. Leitner L, Ujmajuridze A, Chanishvili N, et al. Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial. Lancet Infect Dis. 2021;21(3): 427–436. doi: 10.1016/S1473-3099(20)30330-3

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Vinnik Y.Y., Kuzmenko A.V., Amelchenko A.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
 


Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».